Targacept is slashing its workforce by nearly half, part of a restructuring plan that comes one month after its lead drug candidate, a depression drug, failed the last of a series of phase 3 clinical trials. The company is laying off 65 employees, approximately 46 percent of its staff. Also departing the company will be … Continue reading